Fiber Choice Weight Management Disease Interactions
There are 4 disease interactions with Fiber Choice Weight Management (chromium picolinate / inulin).
Laxatives (applies to Fiber Choice Weight Management) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References (6)
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Laxatives (applies to Fiber Choice Weight Management) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References (8)
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet
- (2001) "Product Information. Citrucel (methylcellulose)." SmithKline Beecham
- (2001) "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Chromium/selenium/zinc (applies to Fiber Choice Weight Management) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.
References (3)
- (2001) "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA
- (2022) "Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc
- "Product Information. Sele-Pak (selenium)." Fujisawa
Trace metals (applies to Fiber Choice Weight Management) malabsorption syndromes
Moderate Potential Hazard, Moderate plausibility.
The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.
References (6)
- (2001) "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA
- (2022) "Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc
- "Product Information. Sele-Pak (selenium)." Fujisawa
- (2001) "Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group
- (2001) "Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical
- (2001) "Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc
Switch to consumer interaction data
Fiber Choice Weight Management drug interactions
There are 82 drug interactions with Fiber Choice Weight Management (chromium picolinate / inulin).
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.